Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangxi Rimag Group CoHKSE:02522 +3.69%14 FCF Margin % is -2.85% as of Dec. 2025. GuruFocus rates HKSE:02522 with a GF Score™ of 14/100. The stock has 6 warning signs investors should review. Among 667 Healthcare Providers & Services companies, Jiangxi Rimag Group Co ranks better than 61.32% on this metric.
The historical rank and industry rank for Jiangxi Rimag Group Co's FCF Margin % or its related term are showing as below:
HKSE:02522'
s FCF Margin % Range Over the Past 10 Years
Min: -39.28 Med: -9.37 Max: 11.29
Current: 6.57
During the past 5 years, the highest FCF Margin % of Jiangxi Rimag Group Co was 11.29%. The lowest was -39.28%. And the median was -9.37%.
HKSE:02522's FCF Margin % is ranked better than 61.32% of 667
companies
in the Healthcare Providers & Services industry
Industry Median: 3.15
vs HKSE:02522: 6.57
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02522 vs HCA, THC, DVA: FCF Margin % Comparison
For the Medical Care Facilities subindustry, Jiangxi Rimag Group Co's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangxi Rimag Group Co FCF Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Jiangxi Rimag Group Co's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Jiangxi Rimag Group Co's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangxi Rimag Group Co (HKSE:02522) has a FCF Margin % of -2.85% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Jiangxi Rimag Group Co and its competitors. According to the industry distribution chart, Jiangxi Rimag Group Co ranks #258 out of 667 companies in the Healthcare Providers & Services industry, placing it in the top 38.7%.
Is Jiangxi Rimag Group Co's FCF Margin % too high?
Jiangxi Rimag Group Co's current FCF Margin % is -2.85%. Based on the distribution chart, Jiangxi Rimag Group Co ranks #258 out of 667 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Jiangxi Rimag Group Co has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Jiangxi Rimag Group Co's FCF Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Jiangxi Rimag Group Co ranks #258 out of 667 companies for FCF Margin %. This puts Jiangxi Rimag Group Co in the upper half of its industry. The industry median FCF Margin % is 3.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Healthcare Providers & Services company?
The median FCF Margin % among Healthcare Providers & Services companies is 3.15, based on 667 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Jiangxi Rimag Group Co and its competitors. For the Healthcare Providers & Services industry, the median FCF Margin % is 3.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangxi Rimag Group Co's current FCF Margin % is -2.85%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangxi Rimag Group Co stock overvalued right now?
Jiangxi Rimag Group Co (HKSE:02522) has a current FCF Margin % of -2.85%. The current FCF Margin % is -2.85%. Jiangxi Rimag Group Co's overall GF Score™ is 14/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Jiangxi Rimag Group Co (HKSE:02522), the current FCF Margin % is -2.85% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Jiangxi Rimag Group Co Ltd is a medical group specializing in medical imaging in China. The company generates revenue through these segments: Imaging Center Services, Imaging Solution Services, and Digital-intelligence services. The Imaging Center Services include examination and diagnostic services to patients and other healthcare consumers via its flagship imaging centers, such as MRI, CT, PET, X-ray, ultrasound and mammography. Majority of the revenue comes from Imaging center services. Geographically, the company operates in Chinese Mainland and Overseas (including Hong Kong and Macau). It generates maximum revenue from Chinese Mainland.
14GF Score
Get the complete analysis for HKSE:02522
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02522 has been successfully added to your 
